<DOC>
	<DOCNO>NCT01263327</DOCNO>
	<brief_summary>This phase I clinical study design evaluate safety novel recombinant HPV 16/18 bivalent vaccine , manufacture Xiamen Innovax Biotech CO. , LTD. , healthy woman 18-55 year age enrolment . Approximately 30 study subject receive novel HPV vaccine administer intramuscularly accord 0-1-6 month schedule .</brief_summary>
	<brief_title>Clinical Trial Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Written inform consent subject prior enrolment ; Female , include , 18 55 year age time enrolment ; Subjects must free obvious health problem ; Not pregnant plan pregnancy ; Pregnant breastfeeding plan pregnancy whole study ( Month 07 ) ; Previous vaccination HPV ; Having severe allergic history immunodeficiency ; Chemotherapy immunosuppressive agent use ;</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>human papillomavirus vaccine</keyword>
</DOC>